GSK confirms 500 mln stg UK investment plans
LONDON, March 22
LONDON, March 22 (Reuters) - GlaxoSmithKline, Britain's biggest drugmaker, confirmed plans on Thursday to invest more than 500 million pounds in manufacturing in Britain and said it had selected Ulverston, northern England, as the site for a previously announced biotech plant.
GSK had already said it aimed to ramp up investment and bring more jobs to Britain in response to government plans to reduce the level of corporation tax applied to income from patents - a move known as a patent box.
The confirmation of the investment strategy comes the day after finance minister George Osborne's budget in which he laid out business-friendly tax plans, including reiterating the introduction of the patent box.
- Exclusive: Angry with Washington, 1 in 4 Americans open to secession
- U.S. immigration protesters drop U.S. border blockade plan
- About 60,000 Syrian Kurds flee to Turkey from Islamic State advance |
- Secret Service investigates after man jumps White House fence, reaches doors
- Kentucky firefighter dies after ice bucket challenge accident